AstraZeneca's Enhertu and Akeso's bispecifics win national coverage in China as CAR-T therapies miss out again
Fierce Pharma
DECEMBER 4, 2024
AstraZeneca’s Daiichi Sankyo-partnered antibody-drug conjugate Enhertu has made it onto China’s national insurance program despite the star med being a part of an ongoing investigation in the count | AstraZeneca’s Daiichi Sankyo-partnered antibody-drug conjugate Enhertu has made it onto China’s national insurance program despite the star med being a part of an ongoing investigation in the country.
Let's personalize your content